Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:ADHD
Date5/2013
Raised$25M
Post IPO Valuation

General Information

Websitealcobra-pharma.co...
CategoryBioTech
Phone1 212.896.1249
Employees

Offices

People

Board of Directors; Audit Committee, Compensation Committee

Tags

Alcobra Pharmaceuticals

Alcobra Pharmaceuticals Inc., which is developing a treatment for attention deficit hyperactivity disorder (ADHD) held its Nasdaq IPO last night (Israel time). Sources said that the company had obtained positive feedback during its road show. Just before the road show, the company expanded its prospectus from issuing 1.36 million share to 2.27 million shares.

Alcobra held the offering at $8 per share, raising a gross $25 million at a company value of $89 million. The company had hoped to raise the money at a share proce of between $10 and $12. It will be traded under the ticker “ADHD”.

Recent Milestones

  • Stock
    Went public with stock symbol NASDAQ:ADHD. (5/21/13)
    Posted 5/22/13 at 11:13pm

Videos

Screenshots

Alcobra Pharmaceuticals screenshot
Above: Homepage
Uploaded: 5/23/13

Stock Price

Sources

Edit This Page
Last Edited 9/2/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy